Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

There’s no cure for psoriasis, but treatment can help you feel better ... adalimumab (Humira), etanercept (Enbrel), or ustekinumab (Stelara). Sometimes, your doctor may recommend phototherapy ...

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

Children with plaque psoriasis or psoriatic arthritis who ... Be sure to talk with your doctor before stopping Stelara treatment. Some important things to discuss with your doctor when considering ...

It was better than Stelara in reaching ... impacting the lives of psoriasis patients,” he added. BE VIVID will follow patients for a year after starting treatment, so additional readouts will ...

Companies in the multi-billion dollar psoriasis market are vying to be the next standard of treatment, and a flood of new data from three drugs showing them superior to Humira and Stelara.

Starjemza gains FDA approval as the eighth ustekinumab biosimilar, enhancing treatment options for rheumatic and ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...

we may see a shift in physician’s choices for psoriasis treatment, says Marfo. The FDA first approved Stelara for the treatment of psoriasis in September 2009, and soon followed this with six ...

Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...

STEQEYMA is approved for the same indications as STELARA, providing consistency in treatment for patients and healthcare providers.[1] STEQEYMA is indicated for the treatment of plaque psoriasis ...